The Cellular Energy Switch and Aging

Edited and approved by Stephen Rose, PhD, MS

Every cell faces a basic accounting problem: it must spend energy to stay alive, yet preserve enough to repair itself and respond to changing demands. A protein called AMPK helps manage that balance. Researchers are investigating whether deliberately activating it might influence aging, rather than simply improve a particular metabolic measurement.

A new Aging Cell study reports that compound 991, a direct AMPK activator, extended lifespan in yeast, worms, and fruit flies. In mice, it produced protein patterns the authors describe as favorable for longevity. These laboratory findings do not establish longer life or healthier aging in people. [1]

What the energy sensor does

AMPK stands for AMP-activated protein kinase. A kinase changes the behavior of other proteins by attaching small chemical groups called phosphates. ATP supplies energy for cellular work; AMP and ADP are related molecules whose balance with ATP helps signal whether energy is becoming scarce. AMPK responds to that balance and coordinates a change in priorities. [2]

Broadly, it favors processes that help supply energy and restrains some energy-intensive construction. Its effects include changes in glucose use and fat metabolism. It also interacts with cellular maintenance: autophagy, the controlled breakdown and recycling of cellular material, and pathways that maintain mitochondria, the structures that supply much of a cell's usable energy. [2]

That range makes AMPK interesting for aging research. It connects fuel management with maintenance. Still, a molecule that helps a cell adapt to one situation need not improve every tissue under every condition. AMPK exists in different combinations of protein components, adding another layer of biological complexity. [2]

Why direct activation matters

Metformin, an established diabetes medicine, has complex actions that make AMPK's contribution difficult to isolate. Using a direct activator makes the new investigation more focused, although direct binding alone does not settle every question about an animal's response. [1]

Compound 991 has a substantial research history. A structural study showed how it fits into a pocket between two regions of AMPK and stabilizes their interaction. The researchers combined protein structures with biochemical and cell experiments to examine activation. In everyday terms, the compound helps hold the machinery in a configuration that supports its activity. [3]

This distinction matters for interpretation. A drug's benefit, if there is one, cannot automatically be transferred to another substance merely because both have been described as activating the same pathway. Where they bind, which tissues they reach, and their additional actions can differ.

What the new results establish

The experiments involved fission yeast, the roundworm Caenorhabditis elegans, and the fruit fly Drosophila melanogaster. Lifespan benefits across these different models support further investigation. They provide no number that can be applied to human life expectancy. [1]

The mouse finding represents different evidence. Proteomics measures patterns of proteins. A profile interpreted as favorable for longevity may suggest promising mechanisms, but does not itself demonstrate that an animal lived longer, avoided disease, or maintained its strength. [1]

The distinction between lifespan and healthspan is equally important. Healthspan concerns the years lived with good function and less disease. For a future human therapy, useful outcomes would include preserved mobility, fewer clinically important illnesses, and acceptable safety over time. A persuasive protein pattern could help guide that research, but it would not replace those outcomes.

A convincing research program would connect these levels of evidence. It would ask whether molecular changes are followed by better function, whether benefits persist, and whether treatment creates problems elsewhere. Comparison groups and sufficiently long follow-up would help separate a promising biological response from an intervention worth using in ordinary life.

Why more activation is not automatically better

A different direct AMPK activator, MK-8722, illustrates why translation requires care. In experiments involving rodents and rhesus monkeys, it improved glucose handling but also caused enlargement of the heart, accompanied by increased glycogen, a stored form of carbohydrate. The investigators did not report apparent functional consequences of that enlargement in their experiments. [4]

This was a different compound, so the finding does not establish that 991 produces the same effect. It does show why a favorable metabolic response cannot stand in for a complete safety assessment. Researchers need to determine which tissues benefit, what exposure is appropriate, and whether effects remain acceptable with prolonged treatment.

Direct activation has already reached human research through another compound, PXL770. In a randomized trial of 120 people with fatty liver disease, treatment lasted 12 weeks. The trial did not meet its primary outcome: an improvement in liver fat compared with placebo. Some metabolic findings encouraged further investigation, and treatment was described as well tolerated, but diarrhea was more common with the drug. [5]

That trial tested a metabolic disease, not aging, and it tested PXL770 rather than 991. Together, these studies make the situation clearer: AMPK is a credible research target, while a safe and effective treatment for human longevity remains to be demonstrated.

Exercise and a pill are different experiences

Exercise naturally engages AMPK as working muscles respond to changing energy demands. The pathway participates in fuel use and adaptations involving mitochondria and other features of trained muscle. Yet exercise involves many signals and whole-body changes. Activating one enzyme with a drug cannot be assumed to reproduce that entire experience. [6]

Drug and exercise effects may also interact. In a randomized study of 53 older adults undergoing 12 weeks of aerobic training, metformin blunted gains in insulin sensitivity and muscle mitochondrial respiration. The average fitness gain was also smaller, although that difference was not statistically conclusive. Responses varied, and several other metabolic improvements still occurred. [7]

This finding does not predict what 991 would do. It does caution against assuming that combining interventions described as beneficial for metabolism will always produce additional benefit. Nor is it a reason to stop metformin prescribed for diabetes; clinical decisions should reflect the condition being treated and the individual's response.

How you may be able to benefit

The most useful immediate implication is to support metabolic health through practices with established human guidance. For activity, adults generally aim for at least 150 minutes of moderate effort weekly, or the equivalent in vigorous activity, plus muscle strengthening on two days. Activity can be divided into manageable sessions, and some is better than none. [8]

For someone starting from inactivity, that might mean short walks that gradually become longer, cycling, or another tolerable activity, alongside suitable resistance exercises. The purpose is sustainable function and health. There is no need to chase a supposed maximum AMPK response or treat exhaustion as proof that an activity is slowing aging. Adapt the plan to ability, health conditions, and recovery.

For eating, this experiment does not identify an ideal human diet, fasting schedule, or calorie target. A practical option is an established pattern such as DASH: vegetables, fruit, whole grains, beans, nuts, and appropriate protein foods, with less sodium and fewer foods high in saturated fat. Simple changes include replacing some refined grains with whole grains, adding beans to meals, and choosing unsalted nuts instead of salty snacks. [9]

These choices follow dietary guidance rather than evidence that a particular meal reproduces 991's effects. A useful personal goal is a pattern that fits nutritional needs and can be maintained, assessed through ordinary clinical measures such as blood pressure and glucose when appropriate. A change in a marketed biological-age score would not, by itself, validate this drug mechanism or establish longer life.

It can help to choose one achievable change and review its effects over time: a more consistent walking routine, regular strength work, or a manageable improvement in meals. Progress means a habit that supports daily life, not a laboratory pathway that someone claims to have maximized.

When evaluating products advertised as AMPK activators, look for human trials of the actual product, with meaningful outcomes and adequate safety follow-up. A lifespan result in a laboratory organism is insufficient justification for self-treatment with an experimental compound.

AMPK research offers a plausible route toward future therapies. For now, the new paper strengthens a biological hypothesis. Its value lies in helping researchers design the next experiments, while readers can act on established approaches to activity, nutrition, and metabolic care without waiting for the hypothesis to become a treatment.

References

[1] Dos Santos E, Blickling M, Leiper FC, et al. Direct Pharmacological Activation of AMPK Extends Lifespan in Yeast, Worms and Flies. Aging Cell. 2026;25(10):e70721. doi:10.1111/acel.70721.

[2] Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016;48(7):e245. doi:10.1038/emm.2016.81.

[3] Xiao B, Sanders MJ, Carmena D, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun. 2013;4:3017. doi:10.1038/ncomms4017.

[4] Myers RW, Guan HP, Ehrhart J, et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science. 2017;357(6350):507-511. doi:10.1126/science.aah5582.

[5] Cusi K, Alkhouri N, Harrison SA, et al. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Gastroenterol Hepatol. 2021;6(11):889-902. doi:10.1016/s2468-1253(21)00300-9.

[6] Spaulding HR, Yan Z. AMPK and the Adaptation to Exercise. Annu Rev Physiol. 2022;84:209-227. doi:10.1146/annurev-physiol-060721-095517.

[7] Konopka AR, Laurin JL, Schoenberg HM, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019;18(1):e12880. doi:10.1111/acel.12880.

[8] Centers for Disease Control and Prevention. Adult Activity: An Overview. Updated December 20, 2023. Accessed September 30, 2026.

[9] National Heart, Lung, and Blood Institute. DASH Eating Plan. National Institutes of Health. Updated February 25, 2026. Accessed September 30, 2026.